1. KINERET ® (anakinra) injection, for subcutaneous use. FULL PRESCRIBING INFORMATION [Internet]. [cited 2020 May 25]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103950s5182lbl.pdf
2. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017 Jul;39(5):529-539. DOI: 10.1007/s00281-017-0629-x
3. Wong CK et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004 Apr;136(1):95-103. DOI: 10.1111/j.1365-2249.2004.02415.x
4. Gong J et al. Correlation Analysis Between Disease Severity and Inflammation-related Parameters in Patients with COVID-19 Pneumonia. MedRxiv. 2020 February 27. DOI: 10.1101/2020.02.25.20025643.
5. Временные методические рекомендации Министерства здравоохранения РФ по профилактике, диагностике и лечению новой коронавирусной инфекции (COVID-19). Версия 6 (28.04.2020) [Электронный ресурс]. 2020. Доступно по: https://clck.ru/NCM6x Ссылка активна на 25.05.2020
6. UW Medicine COVID-19 Resource Site [Internet]. University of Washington. 2020. [cited 2020 May 25]; Available from: https://covid-19.uwmedicine.org/Pages/default.aspx
7. Colleges C.A.M. and N. National COVID-19 Clinical Evidence Taskforce [Internet]. 2020. P. Guidelines. [cited 2020 May 25]; Available from: https://covid19evidence.net.au/
8. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. [cited 2020 May 25]; Available from: https://www.covid19treatmentguidelines.nih.gov/
9. Brigham and Women’s Hospital COVID-19 Clinical Guidelines Therapeutics — Anti-IL-1 Agents (Anakinra, Canakinumab, Rilonacept) [Internet]. [cited 2020 May 22]; Available from: https://covidprotocols.org/protocols/therapeutics/#anti-il-1-agents-anakinra-canakinumab-rilonacept
10. Filocamo G et al. Use of anakinra in severe COVID-19: a case report. Int J Infect Dis. 2020 Jul;96:607-609. DOI: 10.1016/j.ijid.2020.05.026
11. Franzetti M et al. Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report. Int J Infect Dis. 2020 Aug;97:215-218. DOI: 10.1016/j.ijid.2020.05.050
12. Lopalco G et al. Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders. Clin Exp Rheumatol. Italy, 2016. Vol. 34, No 3. P. 531- 538.
13. Разъяснения Министерства здравоохранения РФ от 30 октября 2018 г. О ввозе в РФ конкретной партии незарегистрированных лекарственных средств, предназначенных для оказания медицинской помощи по жизненным показаниям конкретного пациента. Доступно по: https://www.garant.ru/products/ipo/prime/doc/71995356/ Ссылка активна на 27.05.2020
